BCR-ABL alternative splicing as a common mechanism for imatinib resistance: Evidence from molecular dynamics simulations

Tai Sung Lee, Wanlong Ma, Xi Zhang, Francis Giles, Jorge Cortes, Hagop Kantarjian, Maher Albitar

Research output: Contribution to journalArticle

Abstract

Rare cases of chronic myelogenous leukemia (CML) express high levels of alternatively spliced BCR-ABL mRNA with a 35-bp insertion (35INS) between ABL kinase domain exons 8 and 9. This insertion results in a frameshift leading to the addition of 10 residues and truncation of 653 residues due to early termination. Sensitive PCR-based testing showed that 32 of 52 (62%) imatinib-resistant CML patients in chronic phase and 8 of 38 (21%) in accelerated or blast crisis expressed varying levels of the alternatively spliced BCR-ABL mRNA. A three-dimensional structural model of the 35INS ABL kinase domain complexed with imatinib was built using homology modeling, followed by molecular dynamics simulations. Simulation results showed that the new residues cause a significant global conformational change, altering imatinib binding in a way similar to that of the T315I mutation and, therefore, providing resistance to imatinib that depends on the level of expression.

Original languageEnglish (US)
Pages (from-to)3834-3841
Number of pages8
JournalMolecular cancer therapeutics
Volume7
Issue number12
DOIs
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

Alternative Splicing
Molecular Dynamics Simulation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphotransferases
Blast Crisis
Messenger RNA
Structural Models
Exons
Polymerase Chain Reaction
Mutation
Imatinib Mesylate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

BCR-ABL alternative splicing as a common mechanism for imatinib resistance : Evidence from molecular dynamics simulations. / Lee, Tai Sung; Ma, Wanlong; Zhang, Xi; Giles, Francis; Cortes, Jorge; Kantarjian, Hagop; Albitar, Maher.

In: Molecular cancer therapeutics, Vol. 7, No. 12, 01.12.2008, p. 3834-3841.

Research output: Contribution to journalArticle

Lee, Tai Sung ; Ma, Wanlong ; Zhang, Xi ; Giles, Francis ; Cortes, Jorge ; Kantarjian, Hagop ; Albitar, Maher. / BCR-ABL alternative splicing as a common mechanism for imatinib resistance : Evidence from molecular dynamics simulations. In: Molecular cancer therapeutics. 2008 ; Vol. 7, No. 12. pp. 3834-3841.
@article{cb1f52b5609a49189049c97f22d21bab,
title = "BCR-ABL alternative splicing as a common mechanism for imatinib resistance: Evidence from molecular dynamics simulations",
abstract = "Rare cases of chronic myelogenous leukemia (CML) express high levels of alternatively spliced BCR-ABL mRNA with a 35-bp insertion (35INS) between ABL kinase domain exons 8 and 9. This insertion results in a frameshift leading to the addition of 10 residues and truncation of 653 residues due to early termination. Sensitive PCR-based testing showed that 32 of 52 (62{\%}) imatinib-resistant CML patients in chronic phase and 8 of 38 (21{\%}) in accelerated or blast crisis expressed varying levels of the alternatively spliced BCR-ABL mRNA. A three-dimensional structural model of the 35INS ABL kinase domain complexed with imatinib was built using homology modeling, followed by molecular dynamics simulations. Simulation results showed that the new residues cause a significant global conformational change, altering imatinib binding in a way similar to that of the T315I mutation and, therefore, providing resistance to imatinib that depends on the level of expression.",
author = "Lee, {Tai Sung} and Wanlong Ma and Xi Zhang and Francis Giles and Jorge Cortes and Hagop Kantarjian and Maher Albitar",
year = "2008",
month = "12",
day = "1",
doi = "10.1158/1535-7163.MCT-08-0482",
language = "English (US)",
volume = "7",
pages = "3834--3841",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - BCR-ABL alternative splicing as a common mechanism for imatinib resistance

T2 - Evidence from molecular dynamics simulations

AU - Lee, Tai Sung

AU - Ma, Wanlong

AU - Zhang, Xi

AU - Giles, Francis

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Albitar, Maher

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Rare cases of chronic myelogenous leukemia (CML) express high levels of alternatively spliced BCR-ABL mRNA with a 35-bp insertion (35INS) between ABL kinase domain exons 8 and 9. This insertion results in a frameshift leading to the addition of 10 residues and truncation of 653 residues due to early termination. Sensitive PCR-based testing showed that 32 of 52 (62%) imatinib-resistant CML patients in chronic phase and 8 of 38 (21%) in accelerated or blast crisis expressed varying levels of the alternatively spliced BCR-ABL mRNA. A three-dimensional structural model of the 35INS ABL kinase domain complexed with imatinib was built using homology modeling, followed by molecular dynamics simulations. Simulation results showed that the new residues cause a significant global conformational change, altering imatinib binding in a way similar to that of the T315I mutation and, therefore, providing resistance to imatinib that depends on the level of expression.

AB - Rare cases of chronic myelogenous leukemia (CML) express high levels of alternatively spliced BCR-ABL mRNA with a 35-bp insertion (35INS) between ABL kinase domain exons 8 and 9. This insertion results in a frameshift leading to the addition of 10 residues and truncation of 653 residues due to early termination. Sensitive PCR-based testing showed that 32 of 52 (62%) imatinib-resistant CML patients in chronic phase and 8 of 38 (21%) in accelerated or blast crisis expressed varying levels of the alternatively spliced BCR-ABL mRNA. A three-dimensional structural model of the 35INS ABL kinase domain complexed with imatinib was built using homology modeling, followed by molecular dynamics simulations. Simulation results showed that the new residues cause a significant global conformational change, altering imatinib binding in a way similar to that of the T315I mutation and, therefore, providing resistance to imatinib that depends on the level of expression.

UR - http://www.scopus.com/inward/record.url?scp=57749110998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749110998&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-0482

DO - 10.1158/1535-7163.MCT-08-0482

M3 - Article

C2 - 19056677

AN - SCOPUS:57749110998

VL - 7

SP - 3834

EP - 3841

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -